Education
About Us
Working with TipRanks
Follow Us
Galera Therapeutics (GRTX)
OTHER OTC:GRTX
GRTX Stock Chart & Stats
$0.02
<$0.01(0.99%)
At close: 4:00 PM EST
$0.02
<$0.01(0.99%)
Day’s Range― - ―
52-Week Range$0.02 - $0.06
Previous CloseN/A
Volume48.38K
Average Volume (3M)63.57K
Market Cap
$1.81M
Enterprise Value$148.50M
Total Cash (Recent Filing)$4.47M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.87
Next Earnings
Aug 18, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding75,462,390
10 Day Avg. Volume87,114
30 Day Avg. Volume63,573
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-0.02
Price to Sales (P/S)0.00
P/FCF Ratio-0.21
Enterprise Value/Market Cap81.87
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-19.37
Enterprise Value/Ebitda-6.79
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Galera Therapeutics News
GRTX FAQ
What was Galera Therapeutics’s price range in the past 12 months?
Galera Therapeutics lowest stock price was $0.01 and its highest was $0.06 in the past 12 months.
What is Galera Therapeutics’s market cap?
Galera Therapeutics’s market cap is $1.81M.
When is Galera Therapeutics’s upcoming earnings report date?
Galera Therapeutics’s upcoming earnings report date is Aug 18, 2025 which is 119 days ago.
How were Galera Therapeutics’s earnings last quarter?
Galera Therapeutics released its earnings results on May 19, 2025. The company reported -$0.016 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.016.
Is Galera Therapeutics overvalued?
According to Wall Street analysts Galera Therapeutics’s price is currently Overvalued.
Does Galera Therapeutics pay dividends?
Galera Therapeutics does not currently pay dividends.
What is Galera Therapeutics’s EPS estimate?
Galera Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Galera Therapeutics have?
Galera Therapeutics has 75,462,390 shares outstanding.
What happened to Galera Therapeutics’s price movement after its last earnings report?
Galera Therapeutics reported an EPS of -$0.016 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Galera Therapeutics?
Currently, no hedge funds are holding shares in GRTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Galera Therapeutics
Galera Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule superoxide dismutase mimetic, which has completed Phase III clinical trial for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC); in Phase IIa clinical trial for the treatment of radiotherapy-induced esophagitis in patients with lung cancer; and in Phase IIa clinical trial for patients with HNC undergoing standard-of-care radiotherapy. It is also involved in developing GC4711, a superoxide dismutase mimetic product candidate, which is in Phase I/II clinical trial in combination with stereotactic body radiation therapy (SBRT) in patients with non-small cell lung cancer and locally advanced pancreatic cancer. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.
Technical Analysis
Q/C Technologies
―
Salarius Pharmaceuticals
―
Scinai Immunotherapeutics
―
Evaxion Biotech
―
Onconetix
―
Ownership Overview
10.50% Insiders
<0.01% Mutual Funds
3.90% Other Institutional Investors
85.60% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---